The new REsolution consortium is a public-private research partnership, supported by the Innovative Medicines Initiative (IMI), with nine partners from academia and the pharmaceutical industry. Starting on June 1, 2021 and with a duration of 2 years, the project aims to understand how genetic variants in humans affect the function of hundreds of cellular transporters.
How do molecules such as vitamins, nutrients and drugs enter our organs and cells? Why do some of us take up certain molecules more easily than others? The REsolution consortium studies how differences in the genetic makeup of so-called transporter genes, encoding proteins that allow molecules to pass cellular membranes, may account for those differences. The REsolution consortium includes universities, research institutes, a small-medium-sized enterprise, and European Federation of Pharmaceutical Industries and Associations (EFPIA) members. The project, led by Pfizer and the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, has received funding through the IMI joint undertaking consisting of €1 million from the H2020 Programme of the European Union and €1 million from in-kind contributions of industry partners.
Funding
The REsolution project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101034439. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA. The IMI is a partnership between the European Union and the European pharmaceutical industry.
Since 2008, IMI has facilitated open collaboration in research to advance the development of, and accelerate patient access to, personalised medicines for the health and wellbeing of all, especially in areas of unmet medical need. www.imi.europa.eu
